[1]水 淼,杨国科,江 江.康柏西普玻璃体腔注射联合普拉洛芬局部给药治疗糖尿病性白内障术后黄斑水肿疗效观察[J].陕西医学杂志,2024,(12):1676-1679.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.018]
　SHUI Miao,YANG Guoke,JIANG Jiang.Efficacy of intravitreal injection of conbercept combined with local administration of pranoprofen on macular edema after diabetic cataract surgery[J].,2024,(12):1676-1679.[doi:DOI:10.3969/j.issn.1000-7377.2024.12.018]
点击复制

康柏西普玻璃体腔注射联合普拉洛芬局部给药治疗糖尿病性白内障术后黄斑水肿疗效观察
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年12期
页码:
1676-1679
栏目:
药物与临床
出版日期:
2024-12-05

文章信息/Info

Title:
Efficacy of intravitreal injection of conbercept combined with local administration of pranoprofen on macular edema after diabetic cataract surgery
作者:
水 淼; 杨国科; 江 江
(安徽医科大学第三附属医院 合肥市第一人民医院眼科,安徽 合肥 230061)
Author(s):
SHUI Miao; YANG Guoke; JIANG Jiang
(Department of Ophthalmology,the Third Affiliated Hospital of Anhui Medical University,Hefei 230061,China)
关键词:
黄斑水肿;  糖尿病;  白内障;  康柏西普;  普拉洛芬;  黄斑厚度
Keywords:
Macular edema;  Diabetic;  Cataract;  Conbercept;  Pranoprofen;  Macular thickness
分类号:
R 774.1
DOI:
DOI:10.3969/j.issn.1000-7377.2024.12.018
文献标志码:
A
摘要:
目的:观察康柏西普玻璃体腔注射联合普拉洛芬局部给药治疗糖尿病性白内障术后黄斑水肿(ME)的疗效。方法:选取糖尿病性白内障术后ME患者106例为研究对象,按照随机数字表法分为pran组(53例)和pran+con组(53例)。pran组在控制血糖等常规治疗基础上给予普拉洛芬滴眼,pran+con组加用康柏西普玻璃体腔注射。比较两组治疗前及治疗后1、3个月眼压,角膜健康情况(角膜内皮细胞密度、六角形细胞比例),最佳矫正视力(BCVA),黄斑中心凹厚度(CMT),治疗3个月后眼底情况,以及不良反应。结果:治疗后1、3个月,两组眼压和CMT随时间降低,且pran+con组低于pran组(均P<0.05); 两组BCVA随时间升高,且pran+con组高于pran组(均P<0.05); 角膜内皮细胞密度和六角形细胞比例组间、时间及交互比较差异无统计学意义(均P>0.05)。治疗后3个月,pran+con组眼底情况优于pran组(P<0.05)。两组不良反应总发生率比较差异无统计学意义P>0.05)。结论:康柏西普玻璃体腔注射联合普拉洛芬局部给药治疗糖尿病性白内障术后ME,可有效降低眼压,改善黄斑区厚度和眼底情况,提升视力水平,对角膜内皮细胞无明显毒性作用,具有良好安全性。
Abstract:
Objective:To observe the efficacy of intravitreal injection of conbercept combined with local administration of pranoprofen in the treatment of macular edema(ME)after diabetic cataract surgery.Methods:A total of 106 patients with ME after diabetic cataract surgery were selected as the research subjects.According to the random number table method,they were divided into pran group(53 cases)and pran+con group(53 cases).The pran group was given pranoprofen eye drops on the basis of routine treatment such as blood glucose control,while the pran+con group was added with intravitreal injection of conbercept.The intraocular pressure,corneal health status(corneal endothelial cell density,proportion of hexagonal cell),best corrected visual acuity(BCVA)and central macular thickness(CMT)before treatment and after 1,3 months of treatment,and fundus condition after 3 months of treatment,and adverse reactions were compared between two groups.Results:After 1,3 months of treatment,intraocular pressure and CMT in the two groups decreased with time,and those in the pran+con group were lower than those in the pran group(all P<0.05); the BCVA of the two groups increased with time,and the BCVA of the pran+con group was higher than that of the pran group(all P<0.05); the corneal endothelial cell density and proportion of hexagonal cell revealed no statistical differences from the aspects of between group,time-point and interaction(all P<0.05). After 3 months of treatment,the fundus condition of the pran+con group was better than that of the pran group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Intravitreal injection of conbercept combined with local administration of pranoprofen can effectively reduce intraocular pressure,improve macular thickness and fundus condition,and enhance visual acuity in the treatment of ME after diabetic cataract surgery.It has no obvious toxic effect on corneal endothelial cells and has good safety.

参考文献/References:

[1] 严宏,宾玥.糖尿病患者白内障手术的综合治疗策略[J].中华实验眼科杂志,2019,37(10):769-773.
[2] 白淑玮,毕春潮,邵娟,等.玻璃体切割手术联合全视网膜光凝术治疗糖尿病视网膜病变临床疗效观察[J].陕西医学杂志,2020,49(12):1569-1572.
[3] 陈雪红,吴子东.糖尿病合并年龄相关性白内障与年龄相关性白内障术后并发症的对比分析[J].中国全科医学,2021,24(5):592-596.
[4] 郭媛,张杰,王振兴.益气固肾明目方联合激光治疗糖尿病视网膜黄斑水肿疗效研究[J].陕西中医,2023,44(11):1570-1572.
[5] 李红,宋艳萍.微视野计对糖尿病性黄斑水肿患者的视功能评估[J].眼科,2021,30(3):236-239.
[6] 朱君雅,姚文,倪锡森,等.糖尿病性黄斑水肿的病理生理机制:神经血管单元研究现状[J].眼科新进展,2023,43(1):66-70.
[7] 吴香丽,谢赟,殷英霞,等.复方血栓通胶囊联合曲安奈德球后注射辅助全视网膜光凝治疗糖尿病黄斑水肿疗效分析[J].陕西中医,2018,39(6):736-738.
[8] 谭舟利,范玮.普拉洛芬对糖尿病患者白内障术后视力和黄斑厚度的影响[J].眼科新进展,2019,39(2):145-148.
[9] 李双,项奕,梅仲明.玻璃体腔注射康柏西普治疗糖尿病性黄斑水肿的疗效[J].中国老年学杂志,2019,39(21):5198-5201.
[10] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华内分泌代谢杂志,2021,37(4):311-398.
[11] 张旭东.实用眼科学[M].北京:科学出版社,2015:89-90.
[12] 许慕东,朱妍,蔡骐,等.总胆红素水平与糖尿病黄斑水肿发病及严重程度的相关性[J].眼科新进展,2023,43(3):216-220.
[13] 皇甫镜如.白内障术后黄斑水肿的诊治新进展[J].中华实验眼科杂志,2019,37(4):312-315.
[14] 张少华,张超,张鹏.阿柏西普治疗不同类型糖尿病黄斑水肿临床效果及影响因素[J].陕西医学杂志,2022,51(7):874-877,881.
[15] 陈孝霞,李旌,辜臻晟.球结膜下注射康柏西普对兔角膜新生血管和淋巴管的抑制作用[J].中华实验眼科杂志,2020,38(7):581-588.
[16] 蒋鹏飞,彭俊,曾志成,等.散血明目片联合康柏西普眼用注射液对湿性老年性黄斑变性患者视网膜厚度的影响[J].中医杂志,2020,61(2):136-141.
[17] 苟文军,李恒,游慧,等.康柏西普对糖尿病性黄斑水肿患者血清中lncRNA MALAT1水平及黄斑中央区厚度的影响[J].国际眼科杂志,2023,23(1):10-16.
[18] 曲勃,刘丹霞,张旺.高眼压状态下角膜内皮的损伤与修复[J].中国医科大学学报,2019,48(8):752-755.
[19] 陈胡挪,庄静宜,方进为,等.不同切口超声乳化人工晶体植入术对老年性白内障患者泪液、眼压与角膜内皮损伤的影响[J].中国老年学杂志,2019,39(16):4016-4019.
[20] 许明林,丁雨溪,马立威,等.糖尿病患者超声乳化白内障摘除联合人工晶状体植入术后角膜内皮细胞的早期变化[J].中国医科大学学报,2020,49(12):1133-1135.
[21] ZHANG Y,GAO Z,ZHANG X,et al.Effect of intravitreal conbercept injection on VEGF-A and -B levels in the aqueous and vitreous humor of patients with proliferative diabetic retinopathy[J].Exp Ther Med,2021,21(4):332.
[22] OBATA S,KAKINOKI M,SAWADA O,et al.Duration of vascular endothelial growth factor suppression after intravitreal injection of brolucizumab and aflibercept in macaque eyes[J].J Ocul Pharmacol Ther,2023,39(3):225-228.
[23] CHATZIRALLI I,PAPADAKOU P,DIMITRIOU E,et al.The effect of intravitreal anti-vascular endothelial growth factor injections on corneal endothelium in patients with diabetic macular oedema[J].Cutan Ocul Toxicol,2021,40(2):66-69.
[24] GHARBIYA M,BRUSCOLINI A,SACCHETTI M,et al.In vivo antivascular endothelial growth factor treatment induces corneal endothelium apoptosis in rabbits through changes in p75NTR-proNGF pathway[J].J Cell Physiol,2018,233(11):8874-8883.
[25] 祁媛媛,闫春晓,金翠华,等.多次玻璃体内注射抗VEGF药物对眼底血管性疾病患者角膜组织形态的影响[J].眼科新进展,2024,44(3):230-234.

相似文献/References:

[1]马为梅,李春花,雷晓琴,等.雷珠单抗玻璃体腔按需注射治疗视网膜分支静脉阻塞继发黄斑水肿疗效研究*[J].陕西医学杂志,2019,(11):1552.
　MA Weimei,LI Chunhua,LEI Xiaoqin,et al.Efficacy of intravitreal PRN ranibizumab treatment for macular edema due to branch retinal vein occlusion[J].,2019,(12):1552.
[2]武卫党,石 磊,张丹凤△,等.达格列净对糖尿病心肌缺血大鼠心肌功能改善作用的实验研究*[J].陕西医学杂志,2020,49(7):778.[doi:DOI:10.3969/j.issn.10007377.2020.07.003]
[3]杨 鲲,何 勇△,孙 静.比伐卢定与普通肝素对冠心病合并2型糖尿病患者经皮冠状动脉介入术凝血功能的影响研究*[J].陕西医学杂志,2020,49(9):1157.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.026]
　YANG Kun,HE Yong,SUN Jing..Effect of bivalirudin and unfractionated heparin on coagulation function in patients with coronary heart disease complicated with type 2 diabetes mellitus undergoing PCI[J].,2020,49(12):1157.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.026]
[4]杨 旭,张致英,康龙丽,等.环状RNA与代谢性疾病研究进展[J].陕西医学杂志,2021,50(1):126.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.033]
　YANG Xu,ZHANG Zhiying,KANG Longli,et al.Advances in circular RNA and metabolic diseases[J].,2021,50(12):126.[doi:DOI:10.3969/j.issn.1000-7377.2021.01.033]
[5]杨 璐,于敬妮,张 赟,等.空腹血糖水平与免疫性葡萄膜炎发病相关性调查研究[J].陕西医学杂志,2021,50(5):630.[doi:DOI:10.3969/j.issn.1000-7377.2021.05.029]
[6]罗诒财,李 昊.糖尿病患者种植体周围炎治疗研究进展[J].陕西医学杂志,2021,50(10):1318.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.036]
　LUO Yicai,LI Hao.Advances in the treatment of peri-implantitis in diabetic patients[J].,2021,50(12):1318.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.036]
[7]李 琳,马红侠.血清25羟维生素D与肥胖/超重糖尿病患者合并甲状腺功能亢进相关性研究[J].陕西医学杂志,2022,51(1):70.[doi:DOI:10.3969/j.issn.1000-7377.2022.01.018]
[8]姜 飞,王东玉.依达拉奉右莰醇联合尿激酶静脉溶栓治疗急性脑梗死合并糖尿病对患者血清氧化应激水平、颈总动脉内-中膜厚度、血清基质金属蛋白酶-12水平的影响[J].陕西医学杂志,2022,51(1):88.[doi:DOI:10.3969/j.issn.1000-7377.2022.01.023]
　JIANG Fei,WANG Dongyu.Effects of edaravone dexborneol combined with urokinase intravenous thrombolysis on serum oxidative stress,common carotid artery intra-media thickness and serum MMP-12 in patients with acute cerebral infarction and diabetes mellitus[J].,2022,51(12):88.[doi:DOI:10.3969/j.issn.1000-7377.2022.01.023]
[9]马昱杭,韩昀屹,韩者艺.顶端钠依赖性胆酸转运体及其在相关疾病中的作用研究进展[J].陕西医学杂志,2022,51(9):1163.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.028]
　MA Yuhang,HAN Yunyi,HAN Zheyi.Advances in apical sodium-dependent bile acid transporter and its role in related diseases[J].,2022,51(12):1163.[doi:DOI:10.3969/j.issn.1000-7377.2022.09.028]
[10]吕艳红,刘朵朵,李 佳.新型冠状病毒奥密克戎变异株感染轻型及无症状患者核酸转阴时间影响因素分析[J].陕西医学杂志,2022,51(12):1511.[doi:DOI:10.3969/j.issn.1000-7377.2022.12.010]

备注/Memo

备注/Memo:
基金项目:安徽省卫生健康委员会科研项目(AHWJ2021B115)
更新日期/Last Update: 2024-12-05